SCHEMBL10241929

SCHEMBL10241929

Cc1cc(C=C(C#N)C#N)ccc1O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 13/20 0.70
ALDH1A1 P00352 9/20 0.70
MAPT P10636 9/20 0.70
MEN1 O00255 8/20 0.70
KMT2A Q03164 8/20 0.70
KDM4E B2RXH2 6/20 0.70
LMNA P02545 6/20 0.70
CYP3A4 P08684 6/20 0.70
HPGD P15428 6/20 0.70
BLM P54132 6/20 0.70
CYP2C9 P11712 5/20 0.70
HSD17B10 Q99714 5/20 0.70
NFKB1 P19838 5/20 0.70
PMP22 Q01453 5/20 0.70
CYP1A2 P05177 5/20 0.70
TSHR P16473 4/20 0.70
ALOX15 P16050 4/20 0.70
SMN1; SMN2 Q16637 4/20 0.70
HIF1A Q16665 4/20 0.70
TP53 P04637 3/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17466923 0.85 ALDH1A1 (0.61) EGFRALDH1A1MAPTMEN1KMT2A
SCHEMBL14006385 0.84 EGFR (0.49) EGFRALDH1A1MAPTMEN1KMT2A
Tyrphostin 23 SCHEMBL29360636 0.82 EGFR (1.00) EGFRALDH1A1MAPTMEN1KMT2A
Tyrphostin 23 SCHEMBL241922 0.82 EGFR (1.00) EGFRALDH1A1MAPTMEN1KMT2A
SCHEMBL10280982 0.80 EGFR (0.45) EGFRALDH1A1MAPTMEN1KMT2A
SCHEMBL3248262 0.79 EGFR (0.82) EGFRALDH1A1MAPTMEN1KMT2A
SCHEMBL10241964 0.78 EGFR (0.74) EGFRALDH1A1MAPTMEN1KMT2A
SCHEMBL10186359 0.78 EGFR (1.00) EGFRALDH1A1MAPTMEN1KMT2A
SCHEMBL8743696 0.77 EGFR (1.00) EGFRALDH1A1MAPTMEN1KMT2A
SCHEMBL15298231 0.76 MEN1 (0.55) EGFRALDH1A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263657-B2 Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-09-11 US disclosed
US-8263657-B2 Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-09-11 US disclosed
US-8097759-B2 Inflammatory cytokine release inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-01-17 US disclosed
US-8097759-B2 Inflammatory cytokine release inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-01-17 US disclosed
US-20100274051-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2010-10-28 US disclosed
US-20100274051-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2010-10-28 US disclosed
US-7700655-B2 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2010-04-20 US disclosed
US-20090192122-A2 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-07-30 US disclosed
US-20090192122-A2 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-07-30 US disclosed
US-20080318956-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2008-12-25 US disclosed
US-20080090779-A1 ANTIALLERGIC AGENTS INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-04-17 US disclosed
US-20080090779-A1 ANTIALLERGIC AGENTS INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-04-17 US disclosed
EP-1847263-A2 Inhibitors against the production and release of inflammatory cytokines Institute of Medicinal Molecular Design, Inc. (JP) 2007-10-24 EP disclosed
EP-1844766-A2 Inhibitors against the production and release of inflammatory cytokines Institute of Medicinal Molecular Design, Inc. (JP) 2007-10-17 EP disclosed
US-20070185059-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US disclosed
US-20070185059-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US disclosed
US-20070185110-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US disclosed
US-20070185110-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US disclosed
US-20070042997-A1 Medicament for treatment of dermal pigmentation INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-02-22 US disclosed
US-20070042997-A1 Medicament for treatment of dermal pigmentation INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090779-A1 ANTIALLERGIC AGENTS NAT1, EPX, HRH2 EGFR 4167/4885ALDH1A1 364/4885MAPT 2536/4885
US-20100274051-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A EGFR 2680/4885ALDH1A1 479/4885MAPT 1849/4885
US-20090192122-A2 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A EGFR 2825/4885ALDH1A1 563/4885MAPT 2086/4885
US-20080318956-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A EGFR 2825/4885ALDH1A1 563/4885MAPT 2086/4885
US-20070185110-A1 Antiallergic agents NAT1, EPX, AHR EGFR 4114/4885ALDH1A1 340/4885MAPT 2469/4885
US-20070185059-A1 Antiallergic agents NAT1, EPX, AHR EGFR 4125/4885ALDH1A1 362/4885MAPT 2415/4885
US-20070042997-A1 Medicament for treatment of dermal pigmentation TYR, XDH, XPA EGFR 1720/4885ALDH1A1 140/4885MAPT 3082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.